Taysha Gene Therapies (TSHA) News
NASDAQ: TSHAHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
3.72-0.05 (-1.33%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
TSHA news summary
We found 7 recent headlines mentioning Taysha Gene Therapies (TSHA): 0 in the past week and 7 in the past 30 days, most often from Nasdaq, Seeking Alpha, GlobeNewswire. For price context, TSHA is down 1.33% at $3.72. The most recent story, "Taysha Q3 Loss Widens On Higher Expenses; REVEAL 6-Month Interim Data Due In H1'27", was published by Nasdaq on Nov 13, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Taysha Gene Therapies headlines
- Taysha Q3 Loss Widens On Higher Expenses; REVEAL 6-Month Interim Data Due In H1'27(RTTNews) - On Thursday, Taysha Gene Therapies, Inc. (TSHA) released third-quarter results, reflecting expanded net loss for the period driven by higher operating expenses. The company also provided…NasdaqTSHA, LEN.B
- Taysha (TSHA) Q3 2026 Earnings Call Transcript@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The MoNasdaq
- Taysha Gene Therapies, Inc. Reports Third Quarter 2026 Financial Results and Corporate UpdateTaysha Gene Therapies, Inc. reported its financial results for the third quarter ended September 30, 2026, and provided a corporate update. For the three months ended September 30, 2026, net loss was…NasdaqTSHA, BF.A
- Taysha Gene Therapies GAAP EPS of -$0.10 beats by $0.03Seeking Alpha
- Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate UpdateREVEAL pivotal and ASPIRE trials evaluating TSHA-102 for Rett syndrome ongoing; expect to report topline data from 6-month interim analysis and FDA feedback on BLA submission pathway in 1H 2027GlobeNewswire
- Taysha Gene Therapies Q3 2026 Earnings PreviewSeeking Alpha
- Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)DALLAS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus…GlobeNewswire